Weatherstone Capital Management buys $352,213 stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Weatherstone Capital Management scooped up 154 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 11, 2016. The investment management firm now holds a total of 7,820 shares of Abbott Laboratories which is valued at $352,213.Abbott Laboratories makes up approximately 0.29% of Weatherstone Capital Management’s portfolio.

Other Hedge Funds, Including , Credit Suisse Ag boosted its stake in ABT in the latest quarter, The investment management firm added 925,709 additional shares and now holds a total of 3,818,763 shares of Abbott Laboratories which is valued at $171,997,086. Abbott Laboratories makes up approx 0.21% of Credit Suisse Ag’s portfolio.First Interstate Bank reduced its stake in ABT by selling 550 shares or 3.02% in the most recent quarter. The Hedge Fund company now holds 17,648 shares of ABT which is valued at $795,042. Abbott Laboratories makes up approx 0.16% of First Interstate Bank’s portfolio.Carnegie Capital Asset Management boosted its stake in ABT in the latest quarter, The investment management firm added 1,777 additional shares and now holds a total of 48,146 shares of Abbott Laboratories which is valued at $2,164,163. Abbott Laboratories makes up approx 0.31% of Carnegie Capital Asset Management’s portfolio.American Century Companies Inc reduced its stake in ABT by selling 372,711 shares or 6.31% in the most recent quarter. The Hedge Fund company now holds 5,536,164 shares of ABT which is valued at $241,764,282. Abbott Laboratories makes up approx 0.27% of American Century Companies Inc’s portfolio.Hochman Cole Investment Advisors reduced its stake in ABT by selling 399 shares or 1.22% in the most recent quarter. The Hedge Fund company now holds 32,391 shares of ABT which is valued at $1,381,476. Abbott Laboratories makes up approx 1.09% of Hochman Cole Investment Advisors’s portfolio.

Abbott Laboratories closed down -0.27 points or -0.61% at $43.9 with 74,01,381 shares getting traded on Tuesday. Post opening the session at $44.37, the shares hit an intraday low of $43.9 and an intraday high of $44.42 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Leave a Reply

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.